Evidence map›Paper›PMID 11122894›Full record

ReviewCurrent oncology reports2000

Angiogenic molecules and mechanisms in breast cancer.

I Wu, M A Moses

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current oncology reports, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

I WuLaboratory for Surgical Research, The Children's Hospital, and Department of Surgery, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA.
M A Moses
Boston Children's Hospital · USHarvard University · US

Funding

NOVEL ANGIOGENESIS INHIBITOR FROM CARTILAGER01CA083106 · NCI · CHILDREN'S HOSPITAL BOSTON · PI MOSES, MARSHA A · 1999 to 2002
$711k
NCI NIH HHS R01 CA83106
6 · The paper itself

Abstract

One of the most promising and exciting anti-cancer strategies is one that is based on the inhibition of angiogenesis. Unlike conventional therapeutic approaches, anti-angiogenic therapy holds the unique promise of treating the disease in the absence of cytotoxicity or drug resistance. The link between angiogenesis and the progression of human breast cancer has been known for over 25 years, yet it is only in recent years, as endogenous stimulators and inhibitors of angiogenesis have been discovered and studied, that the promise of this therapeutic approach for breast cancer has come to be appreciated. This article presents a concise review of recent studies focused on the molecules and mechanisms that are related to the role of angiogenesis in breast cancer.

Indexed as

Neovascularization, PathologicAngiogenesis InhibitorsBreast NeoplasmsDisease ProgressionFemaleHumansMicrocirculationNeoplasm InvasivenessPhenotypeAngiogenesis Inhibitors

Identifiers

PMID11122894
OpenAlexW1966228880

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.